Have a feature idea you'd love to see implemented?
Let us know!
CLLS Cellectis
Price (delayed)
$1.68
Market cap
$168.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.12
Enterprise value
$121.19M
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene
Highlights
The revenue has soared by 84% from the previous quarter and by 47% YoY
The company's gross profit has surged by 84% QoQ and by 51% YoY
CLLS's equity has surged by 70% year-on-year but it is down by 13% since the previous quarter
CLLS's quick ratio is down by 13% year-on-year and by 6% since the previous quarter
The company's debt rose by 12% YoY
Key stats
What are the main financial stats of CLLS
Market
Valuations
Earnings
Shares outstanding
100.09M
Market cap
$168.16M
Enterprise value
$121.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.3
Price to sales (P/S)
4.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.36
Revenue
$36.04M
Gross profit
$35.87M
Net income
-$85.54M
EBIT
-$33.3M
EBITDA
-$14.1M
Free cash flow
$60.44M
Per share
Balance sheet
Liquidity
EPS
-$1.12
EPS diluted
-$1.35
Free cash flow per share
$0.6
Book value per share
$1.29
Revenue per share
$0.36
TBVPS
$3.95
Total assets
$395.88M
Total liabilities
$266.45M
Debt
$112.12M
Equity
$129.42M
Working capital
$128.78M
Debt to equity
0.87
Current ratio
1.78
Quick ratio
1.74
Net debt/EBITDA
3.33
Margins
Efficiency
Dividend
EBITDA margin
-39.1%
Gross margin
99.5%
Net margin
-237.3%
Operating margin
-217.6%
Return on assets
-22.9%
Return on equity
-75.5%
Return on invested capital
-20.9%
Return on capital employed
-14.5%
Return on sales
-92.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLLS stock price
How has the Cellectis stock price performed over time
Intraday
0%
1 week
-20%
1 month
-4.55%
1 year
-41.87%
YTD
-6.67%
QTD
-6.67%
Financial performance
How have Cellectis's revenue and profit performed over time
Revenue
$36.04M
Gross profit
$35.87M
Operating income
-$78.42M
Net income
-$85.54M
Gross margin
99.5%
Net margin
-237.3%
The revenue has soared by 84% from the previous quarter and by 47% YoY
The company's gross profit has surged by 84% QoQ and by 51% YoY
Cellectis's operating margin has soared by 52% from the previous quarter and by 27% YoY
The company's net margin rose by 42% QoQ and by 32% YoY
Growth
What is Cellectis's growth rate over time
Valuation
What is Cellectis stock price valuation
P/E
N/A
P/B
1.3
P/S
4.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.36
The company's EPS rose by 33% YoY and by 7% QoQ
CLLS's equity has surged by 70% year-on-year but it is down by 13% since the previous quarter
The P/B is 24% less than the 5-year quarterly average of 1.7 and 13% less than the last 4 quarters average of 1.5
The revenue has soared by 84% from the previous quarter and by 47% YoY
The price to sales (P/S) is 65% lower than the 5-year quarterly average of 13.2 and 62% lower than the last 4 quarters average of 12.3
Efficiency
How efficient is Cellectis business performance
The company's return on sales has surged by 56% QoQ and by 54% YoY
CLLS's ROA is up by 37% year-on-year and by 7% since the previous quarter
CLLS's return on invested capital is up by 17% since the previous quarter and by 14% year-on-year
The return on equity has grown by 11% year-on-year and by 6% since the previous quarter
Dividends
What is CLLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLLS.
Financial health
How did Cellectis financials performed over time
CLLS's total assets is 49% greater than its total liabilities
Cellectis's total liabilities has soared by 99% YoY and by 3.1% from the previous quarter
CLLS's total assets has surged by 89% year-on-year but it is down by 2.8% since the previous quarter
The company's debt is 13% lower than its equity
CLLS's equity has surged by 70% year-on-year but it is down by 13% since the previous quarter
CLLS's debt to equity is down by 34% year-on-year but it is up by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.